JP2015516378A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516378A5
JP2015516378A5 JP2015502028A JP2015502028A JP2015516378A5 JP 2015516378 A5 JP2015516378 A5 JP 2015516378A5 JP 2015502028 A JP2015502028 A JP 2015502028A JP 2015502028 A JP2015502028 A JP 2015502028A JP 2015516378 A5 JP2015516378 A5 JP 2015516378A5
Authority
JP
Japan
Prior art keywords
thioridazine
subject
cytarabine
concentration
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516378A (ja
Filing date
Publication date
Priority claimed from US13/837,115 external-priority patent/US8809299B2/en
Application filed filed Critical
Publication of JP2015516378A publication Critical patent/JP2015516378A/ja
Publication of JP2015516378A5 publication Critical patent/JP2015516378A5/ja
Pending legal-status Critical Current

Links

JP2015502028A 2012-03-28 2013-03-28 癌の処置のための組み合わせ療法 Pending JP2015516378A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261616658P 2012-03-28 2012-03-28
US61/616,658 2012-03-28
US13/837,115 US8809299B2 (en) 2012-03-28 2013-03-15 Combination therapy for the treatment of cancer
US13/837,115 2013-03-15
PCT/CA2013/050255 WO2013143000A1 (en) 2012-03-28 2013-03-28 Combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2015516378A JP2015516378A (ja) 2015-06-11
JP2015516378A5 true JP2015516378A5 (https=) 2016-05-12

Family

ID=49235839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502028A Pending JP2015516378A (ja) 2012-03-28 2013-03-28 癌の処置のための組み合わせ療法

Country Status (5)

Country Link
US (3) US8809299B2 (https=)
EP (1) EP2830633A4 (https=)
JP (1) JP2015516378A (https=)
CA (1) CA2868629A1 (https=)
WO (1) WO2013143000A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130331381A1 (en) * 2011-02-28 2013-12-12 Mcmaster University Treatment of Cancer WIth Dopamine Receptor Antagonists
US8809299B2 (en) 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer
WO2015080681A1 (en) * 2013-11-29 2015-06-04 Andac Ahmet Cenk Phenothiazine-pyrimidine-2,4(1 h, 3h)-dione compounds for the treatment of cancer
US10874685B2 (en) 2014-04-17 2020-12-29 The Royal Institution For The Advancement Of Learning/Mcgill University Pancreatic cancer therapy and diagnosis
EP2932969A1 (en) 2014-04-17 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Pancreatic cancer therapy and diagnosis
EP3148547B1 (en) * 2014-06-02 2024-01-03 National Yang-Ming University Method for treating drug resistant cancer
EP3158087A4 (en) * 2014-06-19 2018-03-21 Hidenseq Polymorphism in the bcl2 gene determines response to chemotherapy
JP6843225B2 (ja) * 2016-07-28 2021-03-17 チャンスー ヤホン メディテック カンパニー リミテッド 癌の処置のためのドーパミンβ−ヒドロキシラーゼ(DBH)阻害剤およびセロトニン受容体(5−HT)アンタゴニストの使用
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
US11993775B2 (en) * 2020-07-27 2024-05-28 National Cheng Kung University Ubiquitin-specific peptidase 24 inhibitor, medicinal composition and method of delaying or reversing multidrug resistance in cancers using the same
US11827611B2 (en) 2020-07-27 2023-11-28 National Cheng Kung University Ubiquitin-specific peptidase 24 inhibitor, medicinal composition including the same and method of delaying or reversing multidrug resistance in cancers using the same
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN114031574A (zh) * 2021-11-08 2022-02-11 复旦大学附属肿瘤医院 哌罗匹隆及其衍生物在制备抗肿瘤药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072824A1 (en) 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
EP1545544A2 (en) * 2002-07-11 2005-06-29 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
JP2007505914A (ja) 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
US20130331381A1 (en) * 2011-02-28 2013-12-12 Mcmaster University Treatment of Cancer WIth Dopamine Receptor Antagonists
US8809299B2 (en) 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2015516378A5 (https=)
WO2012143497A3 (de) Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
BR112012025017A2 (pt) métodos para melhorar a qualidade do sono.
WO2013087716A3 (de) Fgfr- binder -wirkstoff konjugate und ihre verwendung
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
PH12018500023A1 (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
UA113774C2 (xx) Полімерні наночастинки, що складаються з фінастериду та міноксидилу, спосіб їх виготовлення, водна суспензія, що їх містить, фармацевтична композиція на їх основі та їх застосування
EP2133365A3 (en) Compositions and methods for the treatment of infections and tumors
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
NZ707377A (en) Combination therapy methods for treating proliferative diseases
JP2016501013A5 (https=)
WO2011017195A3 (en) Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
JP2012519182A5 (https=)
JP2010523696A5 (https=)
MX345467B (es) Metodo para inhibicion de actividad desubiquitinante.
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
JP2015528479A5 (https=)
EP4233536A3 (en) Method for enhancing tumor growth
WO2008128191A3 (en) Oral cephalotaxine dosage forms
AR059225A1 (es) Sal de citrato, proceso de preparacion y su actividad en terapia
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента
WO2015100423A3 (en) Methods for treating cancer with ghrh agonists
PE20081548A1 (es) N-[2-(2,1,3-BENZOTIADIAZOL-5-ILAMINO)-6-(2,6-DICLOROFENIL)PIRIDO[2,3-d]PIRIMIDIN-7-IL]-N'-(1,1-DIMETILETIL)-UREA Y DERIVADOS
BR102019022471A2 (pt) nanopartículas magnéticas de óxido de ferro e biopolímeros associadas a fármacos para tratamento de câncer, processo de obtenção e uso